


BIOLOGICS IN PEDIATRIC SEVERE ASTHMA: REAL-WORLD EVIDENCE FROM A SPECIALIZED UNIT IN A TERTIARY PEDIATRIC HOSPITAL


A. Merino Pardo¹, E. Algarra Sánchez¹, M. D. P. García Rodríguez¹, B. Riva de la Hoz¹, E. Matilla García¹, B. Leal Pino¹, E. Nieto Martí¹, M. Echávarri de Miguel¹, A. Abril Cabero¹, L. Fernández Romero¹, M.T. Pozas del Río¹

¹Hospital Infantil Universitario Niño Jesús, Pharmacy, Madrid, Spain

BACKGROUND AND IMPORTANCE



Severe pediatric asthma: frequent exacerbations, healthcare burden, and impaired quality of life.



Biologic therapies changed management, but real-world pediatric evidence remains limited



Pediatric Severe-Asthma Units (PSAU)


- Multidisciplinary
- Pharmacists → key role
- Treatment optimization
- Safety
- Adherence support

AIM AND OBJECTIVES

Describe real-world characteristics and outcomes of **paediatric patients** receiving **biologic therapy** in a PSAU.

MATERIAL AND METHODS

Retrospective, observacional study of patients with severe asthma treated with biologics in a PSAU of a tertiary paediatric hospital



RESULTS

BASELINE CHARACTERISTICS

Total Cohort: **N=44**

♂ Sex: **59.1% Female**

Age at Initiation (Years)

Median

11.3

Range (3.0 – 18.1)

Weight (kg)

Median

41.6

Range (13.5 – 101.7)

COMORBIDITIES

Prevalence: **97.7%** (≥1 comorbidity)


Distribution

Allergy Only **58.1%**

Allergy + Atopic Dermatitis **41.9%**

PHARMACEUTICAL MANAGEMENT

Biologic Prescription Pattern



Pharmacy Activity

308 Pharmaceutical care consultations performed

Treatment Adherence

Median

100%

Range (84.85 – 100)

OUTCOMES & SAFETY

Healthcare Utilization (Annualized)

Metric	Pre-Initiation	Post-Initiation
1 Emergency Visits	Median 1 (0–13)	Median 0 (0–7)
2 Hospital Admissions	Median 0 (0–6)	Median 0 (0–4)

Safety Profile

Adverse Reactions (ARs): **13.6%** (n=6)


- Local injection site reactions, Pruritus, Headache

CONCLUSION AND RELEVANCE



Biologic therapy.

- ↑ Adherence
- ↓ Hospital visits and admissions



Hospital pharmacists

Patient monitoring and support



Further studies should incorporate **long-term outcomes, lung function, and patient-reported measures** to strengthen evidence for clinical practice.

ATC code



Abstract Number: 4CPS-240